Possible scenario
Strong Nasdaq Debut
42% Chance
Oura's rapid revenue growth, the broader IPO reopening, and cornerstone interest from Eli Lilly and Dragoneer support a strong bookbuild. Investors treat the deal as a scarce public-market play on wearables, sleep tracking, and metabolic-health data.
Secondary impacts
- Technology +0.3%
- Healthcare +0.2%
- Consumer Cyclicals +0.1%
Tickers
- DXCM+0.5%
- LLY+0.2%
Portfolio impact
S&P 500+0.1%
Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.
Keeping an eye on this scenario?
Tilt can alert you when its probability or impact shifts, or send you a recommendation when it crosses a threshold.